(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 January 2022 (06.01.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/006283 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2021/039911

(22) International Filing Date:
30 June 2021 (30.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/046,133	30 June 2020 (30.06.2020)	US
63/052,093	15 July 2020 (15.07.2020)	US
63/071,092	27 August 2020 (27.08.2020)	US

(71) Applicant: **VIELA BIO, INC.** [US/US]; One MedImmune Way, First Floor, Area Two, Gaithersburg, Maryland 20878 (US).

(72) Inventors: **REES, William**; c/o Viela Bio, Inc., One MedImmune Way, First Floor, Area Two, Gaithersburg, Maryland 20878 (US). **KATZ, Eliezer**; c/o Viela Bio, Inc., One MedImmune Way, First Floor, Area Two, Gaithersburg, Maryland 20878 (US). **SMITH, Michael**; c/o Viela Bio, Inc., One MedImmune Way, First Floor, Area Two, Gaithersburg, Maryland 20878 (US). **MITTEREDER, Nanette**; c/o Viela Bio, Inc., One MedImmune Way, First Floor, Area Two, Gaithersburg, Maryland 20878 (US).

(74) Agent: **BROWN, Fraser** et al.; Cooley LLP, 1299 Pennsylvania Avenue, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS OF TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER

(57) Abstract: Methods of treating neuromyelitis optica spectrum disorder (NMOSD) are disclosed herein. In particular, methods of treating NMOSD in a subject identified as having a higher or lower level of NMOSD-disease activity, *e.g.*, by serum glial fibrillary acidic protein concentration, are provided.




FIG. 1

[Continued on next page]

WO 2022/006283 A2

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*